<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04650126</url>
  </required_header>
  <id_info>
    <org_study_id>ATM001-001</org_study_id>
    <nct_id>NCT04650126</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Atrosimab (ATM001) in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Randomized, Double-blind, Parallel Group and Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Atrosimab in Response to Single Ascending Intravenous Infusion Doses.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baliopharm Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baliopharm Pty Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, parallel group and placebo-controlled clinical study to assess safety&#xD;
      tolerability, pharmacokinetics and pharmacodynamics of Atrosimab in healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2021</start_date>
  <completion_date type="Anticipated">February 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 23, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetic (PK): Area under the analyte concentration-time curve from time 0 and extrapolated to infinite time (AUC 0-∞)</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area under the plasma concentration curve from administration until the last quantifiable sampling point (AUC 0-t)</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Terminal half life (t1/2)</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Apparent terminal elimination rate constant (λz)</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Mean residence time (MRT)</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Clearance (CL)</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Apparent volume of distribution (Vz)</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Any adverse event, serious adverse event (SAE)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>ATM001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating dose levels of ATM001 administered as single dose in healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATM001 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Escalating dose levels of ATM001 Placebo administered as single dose in healthy subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATM001</intervention_name>
    <description>monovalent anti-TNF-receptor 1 antibody format</description>
    <arm_group_label>ATM001</arm_group_label>
    <other_name>Atrosimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATM001 Placebo</intervention_name>
    <description>ATM001 Placebo</description>
    <arm_group_label>ATM001 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy male subjects&#xD;
&#xD;
          -  body mass index 18-32 kg/m2&#xD;
&#xD;
          -  normal physical examination, clinical laboratory values and ECG&#xD;
&#xD;
          -  additional inclusion criteria apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  febrile or infectious illness at least 7 days prior to the first administration&#xD;
&#xD;
          -  any active physical disease, acute or chronic&#xD;
&#xD;
          -  history of alcohol or drug abuse&#xD;
&#xD;
          -  history of chronic or recurrent metabolic, renal, hepatic, pulmonary,&#xD;
             gastrointestinal, neurological, endocrinological, immunological, psychiatric, or&#xD;
             cardio-vascular disease, myopathies and bleeding tendency&#xD;
&#xD;
          -  additional exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristi McLendon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Q-Pharm Pty Limited</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Herrmann, Dr.</last_name>
    <phone>+41062053910</phone>
    <email>andreas.herrmann@baliopharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Q-Pharm</name>
      <address>
        <city>Herston</city>
        <state>Brisbane</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi Villagonzalo, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

